Compounds > 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone
Page last updated: 2024-09-03

3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone and Disease Exacerbation

3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone has been researched along with Disease Exacerbation in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cebrián, C; Escartín, A; Esquivias, P; Esteva, F; García-González, MA; Lanas, A; Morandeira, A; Ortego, J; Piazuelo, E; Santander, S1
Burnett, MS; Epstein, SE; Ogunmakinwa, J; Rott, D; Zalles-Ganley, A; Zhou, YF; Zhu, J1
Aleksic, N; Delgado, RM; Kar, B; Mann, DL; McKay, K; Nawar, MA; Sivasubramanian, N; Vaughn, WK; Willerson, JT; Wu, KK; Zewail, AM1

Other Studies

3 other study(ies) available for 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone and Disease Exacerbation

ArticleYear
Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats.
    World journal of gastroenterology, 2012, Sep-21, Volume: 18, Issue:35

    Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Barrett Esophagus; Cell Transformation, Neoplastic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Disease Progression; Esophageal Neoplasms; Esophagitis; Esophagus; Female; Furans; Gastroesophageal Reflux; Indomethacin; Membrane Proteins; Metaplasia; Mucous Membrane; Rats; Rats, Wistar; Time Factors

2012
Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice.
    Journal of the American College of Cardiology, 2003, May-21, Volume: 41, Issue:10

    Topics: Animals; Antibodies, Viral; Apolipoproteins E; Arteriosclerosis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytokines; Cytomegalovirus; Cytomegalovirus Infections; Disease Progression; Disease Susceptibility; DNA, Viral; Dose-Response Relationship, Immunologic; Furans; Immunoglobulin G; Isoenzymes; Mice; Mice, Knockout; Prostaglandin-Endoperoxide Synthases; Viral Load; Virus Replication

2003
Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure.
    Circulation, 2004, Mar-23, Volume: 109, Issue:11

    Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Progression; Doxorubicin; Drug Evaluation, Preclinical; Furans; Heart Failure; Inflammation Mediators; Isoenzymes; Mice; Prostaglandin-Endoperoxide Synthases; Reproducibility of Results; Single-Blind Method; Ultrasonography; Ventricular Dysfunction, Left; Ventricular Function, Left

2004